• Home
  • Search Results
  • Change of recipient corneal endothelial cells after non-descemet's stripping automated endothelial keratoplasty in a rabbit model.

Change of recipient corneal endothelial cells after non-descemet's stripping automated endothelial keratoplasty in a rabbit model.

Investigative ophthalmology & visual science (2014-11-20)
Jen-Pin Sun, Fung-Rong Hu, Yan-Ming Chen, Hsiao-Sang Chu, Wei-Li Chen
ABSTRACT

We used a rabbit model to evaluate the interface embedded between the recipient corneas and transplanted donor corneal discs after non-Descemet's stripping automated endothelial keratoplasty (nDSAEK). Unilateral DSAEK and nDSAEK surgeries were performed on New Zealand white rabbits. In vivo confocal microscopy was performed to show: the changes in corneal endothelial cells embedded between the recipient corneas and the transplanted donor corneal discs (CEEB); and the interface opacity by z profile. Immunohistochemistry were performed to evaluate the functional change of CEEB at post-nDSAEK 3 months. Transmission electron microscopy was performed to evaluate the morphology of CEEB after nDSAEK at post-nDSAEK 1, 3, and 6 months. In vivo confocal microscopy showed a time-dependent decrease in the density of CEEB at postoperative 1, 2, or 3 months (P < 0.01). Interface opacity was higher in the nDSAEK group than the DSAEK group at all examination points, but the difference was statistically insignificant. At 3 months after surgery, the CEEB were negative for Na(+)/K(+)-ATPase staining. Staining with TUNEL showed apoptotic changes in some areas. During a 6-month observation, the CEEB showed a time-dependent thickening and loss of uniform thickness of cellular morphology. At 3 and 6 months post nDSAEK, extensions of the cellular processes into the donor graft stroma combined with intracellular vacuoles containing collagen-like materials were also found. After non-Descemet's stripping automated endothelial keratoplasty, the CEEB showed decreased density, loss of pump function, apoptosis and changed morphology. However, the interface opacity was not significantly greater compared with DSAEK eyes.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
DAPI, for nucleic acid staining
Sigma-Aldrich
Dexamethasone, powder, BioReagent, suitable for cell culture, ≥97%
Sigma-Aldrich
Propidium iodide, ≥94.0% (HPLC)
Sigma-Aldrich
Dexamethasone, ≥98% (HPLC), powder
Sigma-Aldrich
Propidium iodide solution, solution (1.0 mg/ml in water)
Sigma-Aldrich
Toluidine Blue, for microscopy (Hist., Vit.)
Sigma-Aldrich
Levofloxacin, 98.0-102.0% anhydrous basis (HPLC)
Supelco
Dexamethasone, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Dexamethasone, powder, γ-irradiated, BioXtra, suitable for cell culture, ≥80% (HPLC)
Sigma-Aldrich
Propidium iodide, ≥94% (HPLC)
Sigma-Aldrich
Xylazine, ≥99%
Supelco
Betamethasone, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Betamethasone, ≥98%
Sigma-Aldrich
Dexamethasone, meets USP testing specifications
USP
Dexamethasone, United States Pharmacopeia (USP) Reference Standard
USP
Levofloxacin, United States Pharmacopeia (USP) Reference Standard
Supelco
Levofloxacin, analytical standard
Dexamethasone, European Pharmacopoeia (EP) Reference Standard
Phenylephrine, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Tropicamide, solid
Supelco
Betamethasone, VETRANAL®, analytical standard
Supelco
Dexamethasone, VETRANAL®, analytical standard
Betamethasone, European Pharmacopoeia (EP) Reference Standard
Dexamethasone for peak identification, European Pharmacopoeia (EP) Reference Standard
USP
Betamethasone, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
β-D-Allose, rare aldohexose sugar
Dexamethasone for system suitability, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Dexamethasone, tested according to Ph. Eur.
Tropicamide, European Pharmacopoeia (EP) Reference Standard
Dexamethasone, British Pharmacopoeia (BP) Assay Standard